Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + leucovorin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Centre Oscar Lambret
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
5-fluorouracil + leucovorin + paclitaxel (often referred to as LV5FU2-paclitaxel in this context) is a combination chemotherapy regimen being investigated for the treatment of metastatic esophageal squamous cell carcinoma (ESCC). The regimen combines the taxane paclitaxel, which stabilizes microtubules to prevent cancer cell division, with the antimetabolite 5-fluorouracil (5-FU) and its biochemical modulator leucovorin (calcium levofolinate). 5-FU inhibits thymidylate synthase, an enzyme essential for DNA synthesis, while leucovorin enhances this inhibition by stabilizing the binding of 5-FU to the enzyme. This specific combination and its administration schedule (LV5FU2) are being evaluated by the Centre Oscar Lambret in the Phase II E-DIS2 trial to determine if continuing treatment beyond six weeks provides a clinical benefit for patients who do not show disease progression after initial therapy.
- Other names
- LV5FU2-paclitaxelLV-5FU2-paclitaxelLV 5FU2-paclitaxelLV5FU2-PLV-5FU2-PLV 5FU2-PLV5FU2 + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + leucovorin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + leucovorin + paclitaxel.